U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Locally Advanced Microsatellite Stable Colorectal Carcinoma

MedGen UID:
1660261
•Concept ID:
C4745036
•
Neoplastic Process

Definition

A microsatellite stable colorectal carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLocally Advanced Microsatellite Stable Colorectal Carcinoma

Professional guidelines

PubMed

Management of Locally Advanced Rectal Cancer: ASCO Guideline.
Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, Cho MT, Cusnir M, Dorth J, George M, Kachnic LA, Kennecke HF, Loree JM, Morris VK, Perez RO, Smith JJ, Strickland MR, Gholami S
J Clin Oncol 2024 Oct;42(28):3355-3375. Epub 2024 Aug 8 doi: 10.1200/JCO.24.01160. PMID: 39116386
Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer.
Xiao W, Luo H, Yao Y, Wang Y, Liu S, Sun R, Chen G
Front Immunol 2023;14:1149122. Epub 2023 Mar 24 doi: 10.3389/fimmu.2023.1149122. PMID: 37033988Free PMC Article
Immunotherapy for the treatment of colorectal cancer.
Lumish MA, Cercek A
J Surg Oncol 2021 Mar;123(3):760-774. doi: 10.1002/jso.26357. PMID: 33595891

Recent clinical studies

Etiology

Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).
Xia F, Wang Y, Wang H, Shen L, Xiang Z, Zhao Y, Zhang H, Wan J, Zhang H, Wang Y, Wu R, Wang J, Yang W, Zhou M, Zhou S, Chen Y, Zhang Z, Wu X, Xuan Y, Wang R, Sun Y, Tong T, Zhang X, Wang L, Huang D, Sheng W, Yan H, Yang X, Shen Y, Xu Y, Zhao R, Mo M, Cai G, Cai S, Xu Y, Zhang Z
J Clin Oncol 2024 Oct;42(28):3308-3318. Epub 2024 Jul 1 doi: 10.1200/JCO.23.02261. PMID: 38950321
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
Yu JH, Xiao BY, Li DD, Jiang W, Ding Y, Wu XJ, Zhang RX, Lin JZ, Wang W, Han K, Kong LH, Zhang XK, Chen BY, Mei WJ, Pan ZZ, Tang JH, Zhang XS, Ding PR
Lancet Oncol 2024 Jul;25(7):843-852. Epub 2024 Jun 6 doi: 10.1016/S1470-2045(24)00203-1. PMID: 38852601
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.
Yang Z, Gao J, Zheng J, Han J, Li A, Liu G, Sun Y, Zhang J, Chen G, Xu R, Zhang X, Liu Y, Bai Z, Deng W, He W, Yao H, Zhang Z
Signal Transduct Target Ther 2024 Mar 11;9(1):56. doi: 10.1038/s41392-024-01762-y. PMID: 38462629Free PMC Article
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer.
Chatila WK, Kim JK, Walch H, Marco MR, Chen CT, Wu F, Omer DM, Khalil DN, Ganesh K, Qu X, Luthra A, Choi SH, Ho YJ, Kundra R, Groves KI, Chow OS, Cercek A, Weiser MR, Widmar M, Wei IH, Pappou EP, Nash GM, Paty PB, Shi Q, Vakiani E, Duygu Selcuklu S, Donoghue MTA, Solit DB, Berger MF, Shia J, Pelossof R, Romesser PB, Yaeger R, Smith JJ, Schultz N, Sanchez-Vega F, Garcia-Aguilar J
Nat Med 2022 Aug;28(8):1646-1655. Epub 2022 Aug 15 doi: 10.1038/s41591-022-01930-z. PMID: 35970919Free PMC Article
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators
Lancet Oncol 2019 Jun;20(6):849-861. Epub 2019 Apr 16 doi: 10.1016/S1470-2045(19)30027-0. PMID: 31003911

Diagnosis

The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review.
Yang L, Cui X, Wu F, Chi Z, Xiao L, Wang X, Liang Z, Li X, Yu Q, Lin X, Gao C
Front Immunol 2024;15:1392499. Epub 2024 May 15 doi: 10.3389/fimmu.2024.1392499. PMID: 38846948Free PMC Article
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action.
Fornaro L, Lonardi S, Catanese S, Nappo F, Pietrantonio F, Pellino A, Angerilli V, Signorini F, Salani F, Murgioni S, Neculaescu IA, Bruno R, Vivaldi C, Ricagno G, Masi G, Bergamo F, Ugolini C, Fassan M
Gastric Cancer 2023 Nov;26(6):958-968. Epub 2023 Jun 29 doi: 10.1007/s10120-023-01411-3. PMID: 37382783
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators
Lancet Oncol 2019 Jun;20(6):849-861. Epub 2019 Apr 16 doi: 10.1016/S1470-2045(19)30027-0. PMID: 31003911
Is increased colorectal screening effective in preventing distant disease?
Augustus GJ, Roe DJ, Jacobs ET, Lance P, Ellis NA
PLoS One 2018;13(7):e0200462. Epub 2018 Jul 12 doi: 10.1371/journal.pone.0200462. PMID: 30001362Free PMC Article
Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy.
Du C, Zhao J, Xue W, Dou F, Gu J
Histopathology 2013 Apr;62(5):723-30. Epub 2013 Feb 21 doi: 10.1111/his.12069. PMID: 23425253

Therapy

Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
Yu JH, Xiao BY, Li DD, Jiang W, Ding Y, Wu XJ, Zhang RX, Lin JZ, Wang W, Han K, Kong LH, Zhang XK, Chen BY, Mei WJ, Pan ZZ, Tang JH, Zhang XS, Ding PR
Lancet Oncol 2024 Jul;25(7):843-852. Epub 2024 Jun 6 doi: 10.1016/S1470-2045(24)00203-1. PMID: 38852601
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.
Yang Z, Gao J, Zheng J, Han J, Li A, Liu G, Sun Y, Zhang J, Chen G, Xu R, Zhang X, Liu Y, Bai Z, Deng W, He W, Yao H, Zhang Z
Signal Transduct Target Ther 2024 Mar 11;9(1):56. doi: 10.1038/s41392-024-01762-y. PMID: 38462629Free PMC Article
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.
Wang F, Jin Y, Wang M, Luo HY, Fang WJ, Wang YN, Chen YX, Huang RJ, Guan WL, Li JB, Li YH, Wang FH, Hu XH, Zhang YQ, Qiu MZ, Liu LL, Wang ZX, Ren C, Wang DS, Zhang DS, Wang ZQ, Liao WT, Tian L, Zhao Q, Xu RH
Nat Med 2024 Apr;30(4):1035-1043. Epub 2024 Mar 4 doi: 10.1038/s41591-024-02813-1. PMID: 38438735
Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, Fukuoka S, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Wakabayashi M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Suzuki Y, Sato A, Nishikawa H, Ito M, Yoshino T
Clin Cancer Res 2022 Mar 15;28(6):1136-1146. doi: 10.1158/1078-0432.CCR-21-3213. PMID: 35063964Free PMC Article
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators
Lancet Oncol 2019 Jun;20(6):849-861. Epub 2019 Apr 16 doi: 10.1016/S1470-2045(19)30027-0. PMID: 31003911

Prognosis

Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).
Xia F, Wang Y, Wang H, Shen L, Xiang Z, Zhao Y, Zhang H, Wan J, Zhang H, Wang Y, Wu R, Wang J, Yang W, Zhou M, Zhou S, Chen Y, Zhang Z, Wu X, Xuan Y, Wang R, Sun Y, Tong T, Zhang X, Wang L, Huang D, Sheng W, Yan H, Yang X, Shen Y, Xu Y, Zhao R, Mo M, Cai G, Cai S, Xu Y, Zhang Z
J Clin Oncol 2024 Oct;42(28):3308-3318. Epub 2024 Jul 1 doi: 10.1200/JCO.23.02261. PMID: 38950321
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.
Yang Z, Gao J, Zheng J, Han J, Li A, Liu G, Sun Y, Zhang J, Chen G, Xu R, Zhang X, Liu Y, Bai Z, Deng W, He W, Yao H, Zhang Z
Signal Transduct Target Ther 2024 Mar 11;9(1):56. doi: 10.1038/s41392-024-01762-y. PMID: 38462629Free PMC Article
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, Mathews C, O'Malley DM, Kristeleit R, Boni V, Gravina A, Banerjee S, Miller R, Pikiel J, Mirza MR, Dewal N, Antony G, Dong Y, Zografos E, Veneris J, Tinker AV
Clin Cancer Res 2023 Nov 14;29(22):4564-4574. doi: 10.1158/1078-0432.CCR-22-3915. PMID: 37363992Free PMC Article
Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, Fukuoka S, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Wakabayashi M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Suzuki Y, Sato A, Nishikawa H, Ito M, Yoshino T
Clin Cancer Res 2022 Mar 15;28(6):1136-1146. doi: 10.1158/1078-0432.CCR-21-3213. PMID: 35063964Free PMC Article
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators
Lancet Oncol 2019 Jun;20(6):849-861. Epub 2019 Apr 16 doi: 10.1016/S1470-2045(19)30027-0. PMID: 31003911

Clinical prediction guides

Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
Yu JH, Xiao BY, Li DD, Jiang W, Ding Y, Wu XJ, Zhang RX, Lin JZ, Wang W, Han K, Kong LH, Zhang XK, Chen BY, Mei WJ, Pan ZZ, Tang JH, Zhang XS, Ding PR
Lancet Oncol 2024 Jul;25(7):843-852. Epub 2024 Jun 6 doi: 10.1016/S1470-2045(24)00203-1. PMID: 38852601
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.
Wang F, Jin Y, Wang M, Luo HY, Fang WJ, Wang YN, Chen YX, Huang RJ, Guan WL, Li JB, Li YH, Wang FH, Hu XH, Zhang YQ, Qiu MZ, Liu LL, Wang ZX, Ren C, Wang DS, Zhang DS, Wang ZQ, Liao WT, Tian L, Zhao Q, Xu RH
Nat Med 2024 Apr;30(4):1035-1043. Epub 2024 Mar 4 doi: 10.1038/s41591-024-02813-1. PMID: 38438735
Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions.
Chen JT, Zhou YW, Han TR, Wei JL, Qiu M
Front Immunol 2023;14:1269341. Epub 2023 Nov 13 doi: 10.3389/fimmu.2023.1269341. PMID: 38022667Free PMC Article
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, Mathews C, O'Malley DM, Kristeleit R, Boni V, Gravina A, Banerjee S, Miller R, Pikiel J, Mirza MR, Dewal N, Antony G, Dong Y, Zografos E, Veneris J, Tinker AV
Clin Cancer Res 2023 Nov 14;29(22):4564-4574. doi: 10.1158/1078-0432.CCR-22-3915. PMID: 37363992Free PMC Article
Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, Fukuoka S, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Wakabayashi M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Suzuki Y, Sato A, Nishikawa H, Ito M, Yoshino T
Clin Cancer Res 2022 Mar 15;28(6):1136-1146. doi: 10.1158/1078-0432.CCR-21-3213. PMID: 35063964Free PMC Article

Recent systematic reviews

Management of Locally Advanced Rectal Cancer: ASCO Guideline.
Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, Cho MT, Cusnir M, Dorth J, George M, Kachnic LA, Kennecke HF, Loree JM, Morris VK, Perez RO, Smith JJ, Strickland MR, Gholami S
J Clin Oncol 2024 Oct;42(28):3355-3375. Epub 2024 Aug 8 doi: 10.1200/JCO.24.01160. PMID: 39116386
The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review.
Yang L, Cui X, Wu F, Chi Z, Xiao L, Wang X, Liang Z, Li X, Yu Q, Lin X, Gao C
Front Immunol 2024;15:1392499. Epub 2024 May 15 doi: 10.3389/fimmu.2024.1392499. PMID: 38846948Free PMC Article
Microsatellite instability and response to neoadjuvant chemoradiotherapy in rectal cancer: A systematic review and meta-analysis.
O'Connell E, Reynolds IS, McNamara DA, Prehn JHM, Burke JP
Surg Oncol 2020 Sep;34:57-62. Epub 2020 Apr 2 doi: 10.1016/j.suronc.2020.03.009. PMID: 32891354

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...